| Literature DB >> 34198914 |
Martha Mantzanidou1, Eleni Pontiki1, Dimitra Hadjipavlou-Litina1.
Abstract
The five-membered hetEntities:
Keywords: analgesic activity; anti-arthritis; anti-inflammatory activities; antioxidant activities; docking study; lipoxygenase inhibition; pyrazoles; pyrazolines
Mesh:
Substances:
Year: 2021 PMID: 34198914 PMCID: PMC8201324 DOI: 10.3390/molecules26113439
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of drugs bearing the pyrazole moiety.
Scheme 1Synthesis of the novel derivatives.
Substituted pyrazoles and pyrazoline derivatives.
| Compd | Template | Ar1 | Ar2 |
|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
Theoretical calculation of the properties associated with energy and charge distribution with the program Spartan v.5.1.3. Lipophilicity values: experimental RM% (RM values are the average of at least five measurements; SD: standard deviation < 10%). Theoretically calculated clog P values calculated using the C-QSAR Program, Biobyte.
| Compd. | Δ | SM2 (kcal/mol) | Surface (Ǻ2) | (Ǻ3) (MV) | Dipole | LPSP | RM a (±SD) a | clog | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
| −7.65 | 2.15 | 9.80 | −6.29 | 321.20 | 318.74 | 2.66 | 4.19 | 0.22 ± 0.2 | 4.77 |
|
| −7.67 | 2.64 | 10.31 | −11.04 | 329.46 | 320.31 | 5.84 | 3.36 | 0.23 ± 0.03 | 4.30 |
|
| −8.44 | 2.39 | 10.83 | −25.72 | 450.99 | 439.09 | 2.44 | 4.84 | 0.68 ± 0.05 | 7.40 |
|
| −7.84 | 2.86 | 10.70 | −8.24 | 419.96 | 410.67 | 1.57 | 5.63 | 0.72 ± 0.06 | 6.15 |
|
| −8.08 | 2.78 | 10.86 | −10.96 | 434.69 | 422.90 | 4.27 | 5.96 | 0.87 ± 0.07 | 6.69 |
|
| −7.73 | 2.48 | 10.21 | −12.79 | 349.38 | 340.28 | 2.32 | 2.22 | −0.07 ± 0.01 | 4.97 |
|
| −7.78 | 2.07 | 9.85 | −7.37 | 382.80 | 376.11 | 1.44 | 4.17 | −0.59 ± 0.05 | 6.89 |
|
| −8.46 | 2.23 | 10.69 | −7.27 | 412.08 | 403.67 | 2.38 | 3.64 | 0.41 ± 0.02 | 6.78 |
a SD standard deviation < 10%.
Interaction with the stable radical 1,1-diphenyl-picrylhydrazyl (DPPH), In vitro lipoxygenase (LOX) inhibitory activity at 100 µM (LOX%).
| Compd. | RA% 50 µM | RA% 50 µM | RA% 100 µM | RA% 100 µM | RA% 200 µM | RA% 200 µM | LOX |
|---|---|---|---|---|---|---|---|
|
| 15.0 | 20.0 | 22.9 | 32.0 | 37.2 | 49.3 | 35 |
|
| 19.3 | 25.0 | 26.1 | 33.6 | 34.9 | 44.4 | 17 |
|
| 17.1 | 22.4 | 41.9 | 44.0 | 49.4 | 59.2 | 42 |
|
| 6.3 | 9.5 | 19.4 | 37.4 | 9.4 | 14.9 | 13 |
|
| 9.5 | 13.0 | 14.8 | 17.8 | 25.6 | 30.1 | 16 |
|
| 21.0 | 24.7 | 34.7 | 38.8 | 50.1 | 59.5 | 3 |
|
| 9.0 | 12.7 | 11.2 | 13.6 | 22.5 | 27.7 | 60 (IC50 = 80 μM) |
|
| 6.7 | 9.5 | 7.8 | 9.6 | 17.2 | 20.9 | 26 |
|
| 81 | 83 | 87 | 93 | 94 | 96 | 93 (0.45 μΜ) |
% Anti-lipid peroxidation (AAPH), decolorization activity ABTS+ % assays. In vivo anti-inflammatory activity (CPE%).
| Compd. | AAPH% | ABTS+ % | CPE a % |
|---|---|---|---|
|
| 89 | no | no |
|
| 78 | no | 27.0 * |
|
| 100 | no | 38.0 * |
|
| 96 | 15 | 63.0 ** |
|
| 98 | 30 | 56.0 ** |
|
| 95 | no | 30.0 * |
|
| 100 | no | 33.0 * |
|
| 97 | no | 16.0 * |
|
| 93 | 91 | - |
|
| - | - | 47 ** |
* p < 0.01, ** p < 0.05. a % of reduction in the rat paw edema (CPE%) induced by carrageenin at the dose of 0.0057 mmol/Kg/body weight. No: no action under the experimental conditions.
In vitro assay for the determination of the type of inhibition of lipoxygenase (LOX).
| LLA *-C | 2g-LOX | NDGA-LOX |
|---|---|---|
| 50 µM | 89.6 | 39.3 |
| 100 µM | - | 36.2 |
| 200 µM | - | 6.6 |
* Linoleic acid sodium salt concentration.
In vivo analgesic activities of 2d and 2e, % inhibition of writhing responses (Writhing inhibition%).
| Compound | Writhing Inhibition (%) a |
|---|---|
| 2d | 54.2 * |
| 2e | 66.1 * |
| Aspirin | 77 ** |
* p < 0.01, ** p < 0.05; a Dose of the administered 0.0057 mmol/kg body weight.
Assessment of the preventive action of 2d on the adjuvant-induced disease (AID). Manifestations (body weight change, liver weight change, zoxazolamine paralysis) in comparison to indomethacin (IMA), used as a reference compound.
| Examined Parameters (mean ± SD) | AID Rats Treated with 2d | AID Rats Treated with IMA | AID Rats-Controls Treated only with the Liquid Vehicle | Absolute Controls, Normal Animals Treated only with the Liquid Vehicle |
|---|---|---|---|---|
| Percent change in body weight (g ± SD) | 6 ± 0.3 ** | 8.3 ± 0.2 * | 3 ± 0.1 * | 14 ± 2 * |
| Percent change in liver weight (g ± SD) | 7 ± 0.6 * | 6.3 ± 0.4 * | 7.8 ± 0.4 * | 8.7 ± 0.5 ** |
| Zoxazolamine paralysis (minutes ± SD) | 227 ± 17 * | 217 ± 17 ** | 284 ± 19 * | 156 ± 18 * |
* p < 0.01 (Student’s Test), ** p < 0.005 (Student’s Test).
Figure 2Effect of the compound 2d and IMA on the onset and severity of arthritis in AID of rats.
Figure 3Preferred docking pose of 2g (depicted in cyan) bound to soybean lipoxygenase (LOX-1).